Metrochem Vortioxetine Hydrobromide Metrochem Vortioxetine Hydrobromide

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vortioxetine Significantly Improves Overall Functioning in A Global Real-World Study in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Finds that Vortioxetine Helps Patients with MDD and Comorbid Generalized Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma to Introduce Its Version of Vortioxetine in India Under an Exclusive Patent License from Lundbeck","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals receives USFDA Tentative Approval for Vortioxetine Tablets 5 mg, 10 mg, 15 mg, and 20 mg","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Vortioxetine

    Menu

    Vortioxetine

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Sun Pharmaceutical Industries Limited

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sun Pharma to Introduce Its Version of Vortioxetine in India Under an Exclusive Patent License from Lundbeck

              Details:

              Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults. The product is approved in over 80 countries1 , including the US, EU, Canada and Australia.

              Lead Product(s): Vortioxetine Hydrobromide

              Therapeutic Area: Psychiatry/Psychology Product Name: Vortidif

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: H. Lundbeck AS

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement March 30, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Alembic Pharmaceuticals Limited

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Alembic Pharmaceuticals receives USFDA Tentative Approval for Vortioxetine Tablets 5 mg, 10 mg, 15 mg, and 20 mg

              Details:

              USFDA has given tentatively approved ANDA, a therapeutically equivalent reference listed drug product for Vortioxetine-Generic (Vortioxetine), indicated for the treatment of major depressive disorder.

              Lead Product(s): Vortioxetine Hydrobromide

              Therapeutic Area: Psychiatry/Psychology Product Name: Vortioxetine-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              H. Lundbeck AS

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              New Study Finds that Vortioxetine Helps Patients with MDD and Comorbid Generalized Anxiety Disorder

              Details:

              A new study shows that people living with Major Depressive Disorder (MDD) and comorbid Generalized Anxiety Disorder (GAD) benefit from treatment with vortioxetine as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS).

              Lead Product(s): Vortioxetine Hydrobromide

              Therapeutic Area: Psychiatry/Psychology Product Name: Trintellix

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 03, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              H. Lundbeck AS

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vortioxetine Significantly Improves Overall Functioning in A Global Real-World Study in Major Depressive Disorder

              Details:

              In a new real-world study, the ability of Trintellix/Brintellix® (vortioxetine) to improve functioning in family, social, and work life for people living with Major Depressive Disorder was assessed.

              Lead Product(s): Vortioxetine Hydrobromide

              Therapeutic Area: Psychiatry/Psychology Product Name: Trintellix

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Megafine Pharma Vortioxetine Hydrobromide RMU
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Close
              4
              Post Enquiry
              POST ENQUIRY